Screener
Amylyx Pharmaceuticals, Inc. AMLX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:04 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336682
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows used in operating activities: | ||
| Net loss | $(84,707) | $(77,350) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 14,438 | 14,183 |
| Depreciation expense | 141 | 297 |
| Accretion of investment discounts, net | (1,826) | (3,226) |
| Charge for in-process research and development ("IPR&D") milestones | 4,000 | — |
| Other non-cash items | 84 | 264 |
Item 1. Financial Statements.
FAQ
- What is Amylyx Pharmaceuticals, Inc.'s stock-based comp?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported stock-based comp of $8.32M in Q2 2026.
- How has Amylyx Pharmaceuticals, Inc.'s stock-based comp changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s stock-based comp increased by 13.2% year-over-year, from $7.35M to $8.32M.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s stock-based comp has grown at a 72.3% compound annual growth rate (CAGR), from $3.14M to $27.65M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Amylyx Pharmaceuticals, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude